CFO James R. Gruber sold 41,713 shares (41.7K) at $16.15–$16.16 blended average for $673,713.74, reducing stake by 16.9%
CFO James R. Gruber executed two separate sales totaling 41,713 shares for $673,713.74 on August 19–20, 2025, reducing his holdings from 246,466 shares to 204,753 shares post-transaction. The sale occurred near the 52-week high of $20.25—within 18.3% of that peak—while the company trades at 30-day momentum of +14.9% and is up substantially from its 52-week low of $4.01. The company posted annual revenue growth of +23.3% but remains unprofitable, with latest quarterly net income of $-2,585,000.00. The magnitude of the reduction (16.9% of pre-transaction holdings) and execution timing relative to recent price strength warrants examination of whether this reflects portfolio management decisions or forward-looking positioning in a growth-stage, still-unprofitable pharma business.